New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
Sustained improvements in daily pain scores demonstrated in the latest study with Vimpat (lacosamide)
13-Dec-2007 -
UCB announced positive results from a Phase III trial evaluating lacosamide (400 mg per day) in the treatment of diabetic neuropathic pain. With a standard titration regimen, the trial met its primary objective with sustained and statistically significant reduction in average daily pain ...
clinical trials
diabetes
neuropathic pain
+4